Back to Search

A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma

  • Protocol Number: 202312141
  • Principal Investigator: Fehniger, Todd
  • Cancer Types: Gene & Cellular Immunotherapy

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.

Protocol Interventions

Drug: AFM13, Drug: AB-101, Drug: Cyclophosphamide, Drug: Fludarabine, Drug: Interleukin-2